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At a Glance Commentary 72 
Scientific Knowledge on the Subject: Two previous trials of intrapleural fibrinolytics 73 
for malignant pleural effusion demonstrated a significant increase in pleural fluid 74 
drainage, lung re-expansion, a decrease in requirement for supplementary oxygen 75 
therapy but no difference in recurrence rate following pleurodesis in the first 30 days.  76 
What this study adds to the field: In this randomized controlled trial of intrapleural 77 
urokinase versus placebo in 71 patients with non-draining malignant pleural effusion 78 
despite the presence of a patent chest tube, there was no difference in the key 79 
clinical outcomes of dyspnea or time to pleurodesis failure over 1 year. Alternative 80 
palliative measures should be used to relieve breathlessness in this patient group.81 
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Abstract 82 
Rationale: Patients with malignant pleural effusion (MPE) experience breathlessness, 83 
which is treated by drainage and pleurodesis. Incomplete drainage results in residual 84 
dyspnea and pleurodesis failure. Intrapleural fibrinolytics lyse septations within 85 
pleural fluid, improving drainage. 86 
Objectives: To assess the effects of intrapleural urokinase on dyspnea and 87 
pleurodesis success in patients with non-draining malignant effusion. 88 
Methods: Prospective double blind randomised trial; patients with non-draining 89 
effusion were randomly allocated 1:1 to intrapleural urokinase (100,000 IU three 90 
doses 12 hourly) or matched placebo. 91 
Measurements: Co-primary outcome measures: dyspnea (average daily 100mm 92 
visual analogue scores over 28 days) and time to pleurodesis failure to 12 months. 93 
Secondary outcomes: survival, time in hospital and radiographic change. 94 
Main results: 71 subjects randomised (36 received urokinase, 35 placebo) from 12 UK 95 
Centres. Baseline characteristics were similar between groups. There was no 96 
difference in mean dyspnea between groups (mean difference 3·8mm, 95% CI -12 to 97 
4·4mm, p=0·36). Pleurodesis failure rates were similar (urokinase 13/35 (37%), 98 
placebo 11/34 (32%), adjusted hazard ratio 1·2, p=0·65). Urokinase was associated 99 
with a decreased effusion size on chest radiograph (adjusted relative improvement -100 
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19% (95% CI -28 to -11%, p<0·001), reduced hospital stay (1·6 days (95% CI 1·0 to 101 
2·6), p=0·049) and improved survival (69 days versus 48 days, p=0.026). 102 
Conclusions: Use of intrapleural urokinase does not reduce dyspnea or improve 103 
pleurodesis success compared with placebo, and cannot be recommended as an 104 
adjunct to pleurodesis. Other palliative treatments should be used. Improvements in 105 
hospital stay, radiographic appearance and survival associated with urokinase require 106 
further evaluation. 107 
Abstract word count: 250 108 
Key words: fibrinolytic, pleurodesis, dyspnea 109 
 110 
Trial registration information:  111 
• ISRCTN (www.isrctn.com): 12852177  112 
• EudraCT (https://eudract.ema.europa.eu): 2008-000586-26  113 
• MREC (nih.gov.my/web/mrec/): 09/H0604/5 114 
115 
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Introduction 116 
Malignant pleural effusion (MPE) is common, affecting an estimated 200,000 patients 117 
in the UK and USA per year(1, 2), and causes disabling dyspnea(3). Standard 118 
treatment involves drainage via chest tube, followed by artificial synthesis of the 119 
pleural membranes (pleurodesis) to prevent recurrence(3). However, initial drainage 120 
may be incomplete resulting in persistent breathlessness and preventing effective 121 
pleurodesis. This is due to fibrinous adhesions within the pleural space, dividing the 122 
fluid into septations(4). Ultrasound images demonstrate intrapleural fibrinolytics lyse 123 
adhesions and improve drainage in MPE(5).  124 
While fibrinolytics alone are of no value in pleural infection(6, 7), two small trials of 125 
intrapleural fibrinolytics for MPE suggest some benefit(8, 9). Okur et al. randomised 126 
47 patients to either streptokinase or no treatment and demonstrated a significant 127 
increase in pleural fluid drainage and lung re-expansion, but no difference in 128 
recurrence rate following pleurodesis(9). Saydam, et al. conducted a randomised trial 129 
of streptokinase or saline in 40 patients with loculated MPE visible on computer 130 
tomography(8), demonstrating significantly increased drainage, a decrease in 131 
requirement for supplementary oxygen therapy, and a non-significant decrease in 132 
pleural fluid recurrence in the first month following streptokinase. However, no trial to 133 
date has assessed the utility of intrapleural fibrinolysis on clinically meaningful 134 
outcomes in this population.  135 
This trial was conducted to assess the effect of adjunctive intrapleural urokinase on 136 
improving pleurodesis, addressing the key clinical outcomes of dyspnea and 137 
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pleurodesis success in patients with non-draining MPE.  Some of the results of this 138 
study have previously been reported in the form of an abstract(10). 139 
 140 
Methods 141 
Study design 142 
The third Therapeutic Intervention in Malignant Effusion Trial (TIME3) was a double-143 
blind, placebo-controlled randomised trial recruiting in 12 British hospitals. Ethical 144 
and regulatory approval for the study was obtained from NRES South Central – 145 
Oxford A, UK before recruitment commenced and the trial was registered (ISRCTN: 146 
12852177, EudraCT number: 2008-000586-26, MREC number: 09/H0604/5). The 147 
trial was overseen by a Trial Steering Committee that met annually, and by a Data 148 
Monitoring Committee. 149 
 150 
Participants  151 
Adult participants with a diagnosis of MPE with a patent, correctly sited chest tube 152 
inserted for dyspnea relief, and significant residual pleural fluid gave written informed 153 
consent prior to enrolment. The diagnosis was established by either histo-cytological 154 
proof of pleural malignancy, or a recurrent large pleural effusion in the context of 155 
histologically-proven cancer outside the pleural space. For inclusion, patients initially 156 
required >25% opacification of the hemithorax by residual fluid on chest radiograph, 157 
but this was altered in March 2011 to either: >15% opacification of the hemithorax on 158 
chest radiograph; or, >2cm loculated pleural fluid visible on ultrasound. This trial 159 
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modification was made in response to increasing use of thoracic ultrasound in clinical 160 
practise in UK and to improve study recruitment. 161 
Exclusion criteria were: age <18 years, expected survival <28 days, known 162 
underlying trapped lung of sufficient severity that pleurodesis is futile, previous 163 
lobectomy or pneumonectomy on the side of the effusion, pleural infection, previous 164 
intrapleural fibrinolytics, known urokinase allergy, coincidental stroke, major 165 
haemorrhage or major trauma, major surgery in the previous 5 days, chylothorax, 166 
pregnancy, lactating mothers, irreversible bleeding diathesis or platelet count 167 
<100*109, irreversible visual impairment and inability to consent or comply with the 168 
protocol. Initially, patients with highly chemotherapy-responsive tumours, such as 169 
small-cell lung cancer were excluded unless the patient had already undergone 170 
chemotherapy, but this exclusion criterion was removed in March 2011. 171 
 172 
Randomisation and masking 173 
Patients were randomised in a 1:1 ratio to urokinase or matched identical placebo 174 
using minimisation, with a random component of 80%, using a telephone 175 
randomization service provided by the Medical Research Council Clinical Trials Unit, 176 
London. Code break was only available to the trial statistician and this was not 177 
required at any time during the trial.  Minimisation criteria were histologic tissue type 178 
(mesothelioma versus non-mesothelioma), previous pleurodesis (yes or no), World 179 
Health Organisation (WHO) performance status (0-2 or 3/4) and recruiting centre(11).  180 
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Treating physicians, patients and outcome assessors were blinded to treatment 181 
allocation throughout the study. 182 
 183 
Baseline assessments (day 0) 184 
At baseline, patients completed a 100mm visual analogue scale (VAS) score 185 
assessing dyspnea over the preceding 24 hours. The VAS has previously been 186 
validated to assess dyspnea in pleural disease(12) and consists of a 100mm line 187 
anchored with “no breathlessness” at 0mm and “maximum possible breathlessness” 188 
at 100mm(13). Patients were asked to mark the line at a point representing their level 189 
of dyspnea. Patients completed the European Organisation for Research and 190 
Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-30)(14) and 191 
baseline demographic and treatment data were recorded. 192 
 193 
Trial interventions 194 
Three doses of urokinase (100,000 units) or exactly matched placebo vials were 195 
reconstituted in 20ml 0·9% saline and injected intrapleurally at 12 hourly intervals via 196 
the chest tube (days zero to one). Twenty-four hours following the last dose (day 197 
two), a chest radiograph was obtained and talc slurry pleurodesis performed with 4g 198 
sterile high grade talc (Novatech, France) following trial specific procedures based on 199 
the national British Thoracic Society treatment guidelines(3). Pleurodesis was 200 
performed regardless of ongoing fluid drainage volume and chest radiograph 201 
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appearance. The chest tube was removed once significant drainage (>150mls in 202 
each 24 hour period) had ceased. 203 
All participants received treatment of the causative primary tumour in accordance 204 
with current guidelines and oncological advice. 205 
 206 
Trial assessments 207 
Patients were followed up for 12 months after randomization or until death. Patients 208 
completed VAS scores at the same time each day for 28 days and at the three, six 209 
and twelve month assessment points. 210 
Data on pleurodesis failure, the EORTC QLQ-30 questionnaire, assessment of 211 
complications, and health care utilisation were measured at 28 days and three, six 212 
and 12 months. All adverse events (AEs) occurring within the first three days 213 
following randomisation were recorded.  214 
 215 
Trial outcomes 216 
Primary Outcomes 217 
The two co-primary outcome measures were: 218 
1. Mean daily dyspnea over the first 28 days post-enrolment measured by VAS. All 219 
patient completed VAS scores were measured by two independent researchers 220 
and the mean measurement used.  221 
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2. Time to pleurodesis failure, defined as symptomatic ipsilateral pleural fluid 222 
recurrence. This required one of the following, to ensure clinical applicability of 223 
the study result:  224 
• A further ipsilateral drainage procedure to control breathlessness; or 225 
• Symptomatic pleural fluid recurrence as determined by the physician caring for 226 
the patient where a further procedure was not conducted (for reasons 227 
including patient choice, futility or other medical reason (e.g. anticoagulation, 228 
poor performance status)).  229 
 230 
Secondary Outcomes 231 
Predetermined secondary outcomes were:  232 
1. Radiographic change in the area of the pleural effusion (measured as the 233 
difference in the proportion of the ipsilateral hemithorax occupied by the 234 
pleural effusion opacity on chest radiograph) on day two post randomisation. 235 
The chest radiograph pleural opacity was measured using a validated digital 236 
system as has been reported previously(6).  237 
2. Total volume of pleural fluid drained post-randomisation. 238 
3. All cause mortality to 12 months. 239 
4. Length of hospital stay post randomisation.  240 
5. Frequency of serious and non-serious adverse events. 241 
6. Blood parameters including biochemical and full blood count analysis.  242 
 243 
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Statistical Methods 244 
Data were analysed on an intention-to-treat basis, and all randomised patients in 245 
whom an outcome was available were included in the analysis. Analyses were pre-246 
determined prior to data analysis and a full Statistical Analysis Plan was signed off 247 
prior to assessment of any data (full details available in the online supplement). 248 
Analyses were adjusted for minimisation criteria (performance status, mesothelioma 249 
and previous pleurodesis)(15). Stata version 12·1 was used (StataCorp. 2011). 250 
The difference between treatment groups in mean daily dyspnea VAS score over 28 251 
days was calculated using a mixed-effects linear regression model, to account for 252 
days with missing VAS scores (as an unbiased analysis which does not differentiate 253 
between scores missing due to patient death and those missing because the patient 254 
did not complete their VAS score on that day). Study day was modelled as a 255 
continuous variable using fractional polynomials and was included in the model as a 256 
random effect. The model adjusted for the baseline VAS score(16) to increase 257 
statistical precision.  258 
Time to pleurodesis failure was analysed using a competing risk model, with death as 259 
the competing risk. 260 
Mean change in area of pleural effusion on day two (after receipt of trial drug, but 261 
prior to pleurodesis) was calculated using a linear regression model, adjusting for 262 
baseline proportion. 263 
Sample Size Calculation 264 
For the pleurodesis outcome, a 32% pleurodesis failure rate in the urokinase group 265 
and an 80% failure rate in the placebo group was assumed. With 25% loss to follow 266 
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up (from expected mortality known in MPE), 68 patients were required, with 90% 267 
power, 5% significance level.  268 
For the dyspnea outcome, power calculations based on pilot data from patients with 269 
MPE indicated 126 patients were needed to detect a 7mm difference in VAS for 270 
breathlessness (SD =11mm, 90% power, alpha =0·05, with 25% loss to FU), and 271 
therefore a recruitment target of 126 patients was chosen. Towards the end of 272 
recruitment, data published demonstrated the minimally important difference of the 273 
VAS score for dyspnea for patients with pleural effusion was 19mm (95% CI 14-274 
24mm) (12), and using this new data, the sample size required to detect a clinically 275 
important difference in dyspnea would have been 40 patients.  276 
 277 
 278 
Results 279 
The trial CONSORT flow chart is presented in Figure 1. Seventy one patients were 280 
recruited from 12 UK hospitals between 1st September 2009 and 30st June 2014, with 281 
recruitment ending due to expiry of the placebo medication. 36 patients were 282 
randomised to urokinase and 35 to placebo, with the treatment groups well matched 283 
at baseline (table 1).  284 
 285 
Change in VAS dyspnea scores 286 
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In both groups, baseline VAS score was 38mm (standard deviation (SD) 28mm in 287 
urokinase, 25mm in placebo) (table 1). Mean VAS dyspnea over 28 days was 39mm 288 
in the urokinase group and 35mm in the placebo group, equating to an average 289 
mean difference in VAS score over 28 days from baseline of 1·4mm (SD 20mm) in 290 
the urokinase and -3·2mm (SD 21mm) in the placebo groups respectively. There was 291 
no significant difference between the two groups (adjusted mean difference from 292 
baseline between groups -3·8mm, 95% CI -12 to 4·4mm, p=0·36) (Figure 2). 293 
Outcome data was missing in eight patients (three in urokinase group, five in 294 
placebo) due to the following reasons: baseline VAS score only (1); VAS booklets not 295 
returned (7). A total of 34 patients died during the first 28 days post randomisation 296 
(19 urokinase, 15 placebo). 297 
There was no difference in the number of patients achieving a clinically significant 298 
decrease in VAS dyspnea (>=19mm) between the two groups (urokinase 13 patients, 299 
placebo 15 patients, p=0.09). 300 
 301 
Pleurodesis success 302 
There was no significant difference in time to pleurodesis failure, which occurred in 303 
13/35 (37%) of patients receiving urokinase compared with 11/34 (32%) receiving 304 
placebo (adjusted hazard ratio 1·2, p=0·65) (Figure 3). Two patients were excluded 305 
from analysis due to death occurring within three days of randomisation (one in each 306 
treatment group). 307 
 308 
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All cause mortality up to 12 months 309 
Death occurred by 12 months of follow up in 31/36 patients in the urokinase group 310 
and in all patients in the placebo group. Median time to death after randomisation 311 
was significantly more in the urokinase group, with median survival of 69 (IQR 24-312 
123) days in the urokinase group and 48 (IQR 31-80) days in the placebo group 313 
(adjusted analysis for minimisation factors, p=0·026).  314 
 315 
Radiographic changes 316 
Chest radiographs at baseline and day two were available for 47 patients (26 317 
urokinase, 21 placebo). In the urokinase group, size of effusion decreased, but in the 318 
placebo group there was no significant change (urokinase: 35% hemithroax 319 
opacification (SD 20) at enrolment, 23% (SD 15) at day two; placebo group: 42% (SD 320 
21) at baseline and 44% (SD 24) at day two (adjusted analysis for baseline % 321 
opacification, mean difference, placebo vs urokinase -19%, 95% CI -28 to -11%, 322 
p≤0·001). 323 
 324 
Hospital Stay 325 
Patients receiving urokinase had a shorter length of hospital stay (measured as time 326 
from randomization to discharge in patients who survived hospital admission) mean 327 
length of stay =6·2 days (SD 2·7) versus 8·7 days (SD 6·5) in the placebo group 328 
(adjusted hazard ratio 1·6 days (95% CI 1·0 to 2·6), p=0·049). 329 
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 330 
Fluid Output 331 
Data were available for 24/36 patients in the urokinase group and 19/35 patients in 332 
the placebo group. There was no significant difference in total pleural fluid drainage 333 
between the groups from randomisation to tube withdrawal, with a mean drainage 334 
volume of 358ml in the urokinase group (SD 644) and 257ml in the placebo group 335 
(SD 402, adjusted mean difference 169ml (95% CI -111 to 448ml) (p=0·24). 336 
 337 
Change in blood parameters from baseline to day three 338 
There was no difference in change in haemoglobin, prothrombin time or activated 339 
partial thromboplastin time (APTT) between the two groups from baseline to day 340 
three (see eTable 1). Platelet counts were higher in those treated with urokinase 341 
compared to placebo (adjusted difference 39 (95% CI 1·6 to 76, p=0·041). 342 
 343 
Quality of Life 344 
There was no difference in self-reported health status or overall quality of life 345 
between the groups at any time point (adjusted difference in health status 1·6%, 346 
(95% CI -8·6 to 12), p=0·76; adjusted difference in quality of life 7·4% (95% CI -3·2 347 
to 18), p=0·18). 348 
 349 
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Adverse events 350 
Six serious adverse events occurred. Two deaths occurred within days zero to three 351 
due to progression of underlying malignancy (one urokinase, one placebo), two 352 
pleural infections (one urokinase, one placebo), one chest tube wound dehiscence 353 
(placebo) and one post-pleurodesis chest pain delaying discharge (urokinase). No 354 
intrapleural haemorrhage occurred, and one patient (receiving placebo) experienced 355 
systemic (pelvic) bleeding.  356 
 357 
 358 
Discussion 359 
This randomised placebo controlled trial is the first to compare urokinase with 360 
placebo for treatment of septated MPE, and the first intrapleural fibrinolytic trial to 361 
assess clinically meaningful outcomes (dyspnea and pleurodesis). Our results 362 
demonstrate no improvement in dyspnea or pleurodesis success following 363 
intrapleural urokinase despite chest radiographic evidence of significant reduction in 364 
size of pleural effusion.  365 
Study participants in our selected population had a high mortality, demonstrating that 366 
the septated MPE population is likely to represent advanced malignancy. This poor 367 
survival means that interventions requiring hospital admission, such as talc 368 
pleurodesis, should be carefully considered in this population.  369 
15 
 
We observed a small but statistically significant decrease in mortality in the urokinase 370 
group, although it should be noted that fibrinolytics are not recognised to have anti-371 
tumour effects, mortality was a secondary outcome and there was an excess of 372 
patients with lung cancer in the placebo group. This study was conceived before the 373 
development of the LENT score for prognostication in patients with MPEs so data 374 
was not collected to enable us to compare baseline prognosis between the 375 
groups(17). Neither of the previous randomised studies of intrapleural fibrinolytics in 376 
MPE reported mortality outcomes(8, 9), however this potential effect should be 377 
subject to further studies.  378 
Urokinase was associated with a decrease in hospital stay compared to placebo, 379 
despite having no effect on dyspnea or fluid output, and in the presence of improved 380 
chest radiograph appearance in the urokinase group. The reasons for shortened 381 
hospital stay using urokinase are not clear, and require further investigation.  382 
Our results support the findings of Okur, et al and Saydam, et al in the key finding 383 
that lung re-expansion is improved but no change in pleurodesis success following 384 
administration of intrapleural fibrinolytics is observed in patients with septated 385 
MPE(8, 9). This improvement could be due to an increase in fluid output of 386 
approximately 100ml in the urokinase group, although this difference did not reach 387 
statistical significance. Although different fibrinolytics were used in these studies, 388 
there is no reason to hypothesize any difference in efficacy between fibrinolytics. 389 
Intrapleural urokinase was not associated with any adverse reactions, suggesting it is 390 
safe for use in patients with MPE.  391 
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In light of these results, is it appropriate to insert a chest tube and attempt 392 
pleurodesis in patients with a septated MPE which is unlikely to drain? Given the high 393 
mortality demonstrated in this study, we propose that  outpatient treatments (such as 394 
therapeutic aspiration or indwelling pleural catheter insertion) in conjunction with 395 
other palliative treatments for dyspnea (such as low dose opiates) may be more 396 
appropriate for this patient group, aiming at providing dyspnea relief without a 397 
hospital admission. Alternatively, thoracoscopy may allow more effective drainage 398 
prior to pleurodesis in those able to tolerate this procedure. 399 
This study has several limitations. The study did not reach the original recruitment 400 
target. However, this occurred in light of new data on the minimal important 401 
difference in VAS used for measurement of dyspnea. On the basis of the data 402 
published during recruitment for this study, TIME3 would be adequately powered to 403 
exclude a clinically meaningful change in dyspnea following intrapleural urokinase. 404 
Completion of screening logs was variable between centres despite guidelines, with 405 
some sites including all patients with a chest tube for MPE whereas other sites only 406 
included patients fulfilling the eligibility criteria.  407 
The TIME3 study results suggest important potential future areas of research. 408 
Indwelling pleural catheters (IPC) are increasingly used in the treatment of patients 409 
with MPE on the basis of randomised trials demonstrating improvement in dyspnea 410 
and reduced hospital stay(18). Recognised IPC complications include blockage and 411 
development of septations, which are increasingly treated with intrapleural 412 
fibrinolytics. A retrospective case series suggested improvement in pleural fluid 413 
drainage and radiographic appearance using intrapleural fibrinolysis(19), but this 414 
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study demonstrates these are not reliable surrogates for the key clinical outcomes of 415 
dyspnea relief and pleurodesis success. This suggests that prospective controlled 416 
trials are now required to assess the potential clinical benefit and harms of such 417 
treatment in IPC patients.  418 
In summary, intrapleural urokinase does not improve dyspnea or pleurodesis 419 
success compared with placebo in patients with non-draining MPE treated with a 420 
chest tube and should not be routinely used as an adjunct to pleurodesis. This 421 
subgroup of patients have a high mortality and significant residual dyspnea despite 422 
chest tube insertion, and alternative palliative measures should be considered for the 423 
relief of dyspnea. The potential benefits of this treatment in improving hospital stay, 424 
chest radiograph appearances and mortality should be further investigated. 425 
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Table 1: Baseline characteristics of the 71 trial patients by group. 426 
 
 
Placebo  
(N=35) 
Urokinase 
 (N=36) 
Age (yrs)  mean (sd) 71·5 (8·3) 69·5 (10·5) 
Female (%) 17 (49) 13 (36) 
WHO Performance Status 
0-2 (%) 
21 (60) 21 (58) 
Histological tissue type  
(%) 
  
Lung 12 (34) 10 (28) 
Mesothelioma 5 (14)  4 (11) 
Breast 6 (17) 6 (17) 
Gastrointestinal  1 (3) 3 (8) 
Adenocarcinoma of unknown 
primary 
2 (6) 1 (3) 
Ovarian 1 (3) 2 (6) 
Other 8 (23) 10 (28) 
Previously pleurodesed 
(%) 
5 (14) 5 (14) 
Size 12 French chest drain 
(%) 
33 (94) 30 (83) 
% opacification of 42 (21) 35 (20) 
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427 hemithorax by effusion 
(SD) 
Baseline VAS score (mm) 
(SD) 
38 (25) 38 (28) 
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Figure legends 428 
Figure 1: CONSORT diagram to summarise recruitment. 429 
Figure 2: Mean change from baseline in VAS dyspnea following intrapleural 430 
urokinase or placebo. Circles represent mean VAS dyspnea over 28 days for 431 
individual participants, black line represents overall mean of group. Positive change 432 
represents less breathlessness. 433 
Figure 3: Kaplan-Meier curve of time to pleurodesis failure 434 
Figure 4: Time to death by group 435 
436 
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